echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Astellas' new hormone-sensitive prostate cancer drug Xtandi receives EU approval for its new indication

    Astellas' new hormone-sensitive prostate cancer drug Xtandi receives EU approval for its new indication

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Astellas announced that the European Commission has approved a new indication for Xtandi: for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.


    This approval is based on data from the pivotal Phase 3 ARCHS study (NCT02677896).


    The results showed that the study reached the primary endpoint of imaging progression-free survival (rPFS): Compared with the placebo+ADT regimen group, the Xtandi+ADT regimen group significantly reduced the risk of radiological progression or death by 61% (HR=0.


    Original source: Astellas' XTANDI (enzalutamide) approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.